257 related articles for article (PubMed ID: 17580264)
1. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.
McCune JS; Batchelder A; Deeg HJ; Gooley T; Cole S; Phillips B; Schoch HG; McDonald GB
Biol Blood Marrow Transplant; 2007 Jul; 13(7):853-62. PubMed ID: 17580264
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.
Rezvani AR; McCune JS; Storer BE; Batchelder A; Kida A; Deeg HJ; McDonald GB
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1033-9. PubMed ID: 23583825
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia.
Mitsuhashi K; Kako S; Shigematsu A; Atsuta Y; Doki N; Fukuda T; Kanamori H; Onizuka M; Takahashi S; Ozawa Y; Kurokawa M; Inoue Y; Nagamura-Inoue T; Morishima Y; Mizuta S; Tanaka J;
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2194-2200. PubMed ID: 27638362
[TBL] [Abstract][Full Text] [Related]
4. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
Demirer T; Buckner CD; Appelbaum FR; Bensinger WI; Sanders J; Lambert K; Clift R; Fefer A; Storb R; Slattery JT
Bone Marrow Transplant; 1996 Apr; 17(4):491-5. PubMed ID: 8722344
[TBL] [Abstract][Full Text] [Related]
5. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
[TBL] [Abstract][Full Text] [Related]
6. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.
Andersson BS; Madden T; Tran HT; Hu WW; Blume KG; Chow DS; Champlin RE; Vaughan WP
Biol Blood Marrow Transplant; 2000; 6(5A):548-54. PubMed ID: 11071260
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
8. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
[TBL] [Abstract][Full Text] [Related]
9. [Effect of BU and CY versus TBI and CY as conditioning regimens on the efficacy of haploidentical stem cell transplantation in patients with hematologic malignancy].
Shao Q; Han D; Liu D; Zheng X; Dong L; Wang Z; Ding L; Yan H; Wang H; Duan L
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):505-10. PubMed ID: 24985173
[TBL] [Abstract][Full Text] [Related]
10. Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.
McCune JS; Wang T; Bo-Subait K; Aljurf M; Beitinjaneh A; Bubalo J; Cahn JY; Cerny J; Chhabra S; Cumpston A; Dupuis LL; Lazarus HM; Marks DI; Maziarz RT; Norkin M; Prestidge T; Mineishi S; Krem MM; Pasquini M; Martin PJ
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1424-1431. PubMed ID: 30871976
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.
Pidala J; Kim J; Anasetti C; Kharfan-Dabaja MA; Nishihori T; Field T; Perkins J; Perez L; Fernandez HF
J Hematol Oncol; 2010 Oct; 3():36. PubMed ID: 20925957
[TBL] [Abstract][Full Text] [Related]
12. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT.
Cantoni N; Gerull S; Heim D; Halter J; Bucher C; Buser A; Tsakiris DA; Passweg J; Tichelli A; Stern M; Gratwohl A
Bone Marrow Transplant; 2011 Mar; 46(3):344-9. PubMed ID: 20548339
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.
Lombardi LR; Kanakry CG; Zahurak M; Durakovic N; Bolaños-Meade J; Kasamon YL; Gladstone DE; Matsui W; Borrello I; Huff CA; Swinnen LJ; Brodsky RA; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Leuk Lymphoma; 2016; 57(3):666-75. PubMed ID: 26292764
[TBL] [Abstract][Full Text] [Related]
14. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
[TBL] [Abstract][Full Text] [Related]
15. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of two conditioning regimens in treatment of leukemia by allogeneic hematopoietic stem cell transplantation].
Zhang GC; Zheng D; Guan XX; Luo SK; Li J; Peng AH; Tong XZ; Lai FZ; Tan EX; Hong WD
Ai Zheng; 2003 Jun; 22(6):620-3. PubMed ID: 12948413
[TBL] [Abstract][Full Text] [Related]
17. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients.
Slattery JT; Kalhorn TF; McDonald GB; Lambert K; Buckner CD; Bensinger WI; Anasetti C; Appelbaum FR
J Clin Oncol; 1996 May; 14(5):1484-94. PubMed ID: 8622062
[TBL] [Abstract][Full Text] [Related]
18. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.
Copelan EA; Avalos BR; Ahn KW; Zhu X; Gale RP; Grunwald MR; Hamadani M; Hamilton BK; Hale GA; Marks DI; Waller EK; Savani BN; Costa LJ; Ramanathan M; Cahn JY; Khoury HJ; Weisdorf DJ; Inamoto Y; Kamble RT; Schouten HC; Wirk B; Litzow MR; Aljurf MD; van Besien KW; Ustun C; Bolwell BJ; Bredeson CN; Fasan O; Ghosh N; Horowitz MM; Arora M; Szer J; Loren AW; Alyea EP; Cortes J; Maziarz RT; Kalaycio ME; Saber W
Biol Blood Marrow Transplant; 2015 Mar; 21(3):552-8. PubMed ID: 25528388
[TBL] [Abstract][Full Text] [Related]
19. Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients.
Yeh RF; Pawlikowski MA; Blough DK; McDonald GB; O'Donnell PV; Rezvani A; Deeg HJ; McCune JS
Biol Blood Marrow Transplant; 2012 Feb; 18(2):265-72. PubMed ID: 21736869
[TBL] [Abstract][Full Text] [Related]
20. Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.
Seydoux C; Medinger M; Gerull S; Halter J; Heim D; Chalandon Y; Levrat SM; Schanz U; Nair G; Ansari M; Simon P; Passweg JR; Cantoni N
Ann Hematol; 2021 Jan; 100(1):209-216. PubMed ID: 33098041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
